For US healthcare professionals
Indicated for reduction in the duration of severe neutropenia in patients with nonmyeloid
malignancies receiving myelosuppressive anticancer drugs associated with a clinically
significant incidence of febrile neutropenia.
Important Safety Information: Splenic rupture, including
fatal cases, can occur following the administration of human granulocyte colony-stimulating
factors (hG-CSFs). Discontinue GRANIX and evaluate for an enlarged spleen or splenic
rupture in patients who report upper abdominal or shoulder pain after receiving
Storage, administration & dosing
Cost & reimbursement
Trusted to take a bite out of G-CSF acquisition
Based on wholesale acquisition cost (WAC) of short-acting G-CSF products as
Transactional prices may vary; contact your supplier for actual prices.
Do you know someone who might be interested in GRANIX? Fill out the form below to
send a link to this page to your colleague.
Teva does not keep the information you provide on this page. Your email address
is needed only so that the email recipient may reply to you. Therefore, Teva will
not track, review, or edit your messages sent using the "Tell a colleague" service.
Teva will have access to summary information about the use of this feature by all
Web site visitors, but no details about you, your message, or your colleague.
Full Prescribing Information.
Reference: 1. This information is an estimate
derived from the use of information under license from the following IMS Health
Information Service: IMS National Sales Perspective, GRANIX® (tbo-filgrastim) Injection micrograms by non-federal
hospital channel February 2016. IMS expressly reserves all rights, including rights
of copying, distribution, and republication (micrograms calculated as eaches x strength).
©2016 Cephalon, Inc., a wholly-owned subsidiary of Teva Pharmaceutical Industries
Ltd. GRANIX is a registered trademark of Teva Pharmaceutical Industries Ltd.
All rights reserved. GRX-40884 June 2016